Dynamics of the content of immunoglobulin G to severe acute respiratory syndrome-2 in convalescents who have had a new coronavirus infection
Open Access
- 4 January 2023
- journal article
- research article
- Published by ECO-Vector LLC in Bulletin of the Russian Military Medical Academy
- Vol. 24 (4) , 659-666
Abstract
The study investigated the dynamics of class G immunoglobulins to severe acute respiratory syndrome-2 coronavirus in the blood serum of convalescents who had a new coronavirus infection for 6 months after the polymerase chain reaction conversion. Among the most common symptoms, 30 (73.8%) convalescents had an increase in body temperature to 38C, 32 (83.3%) had asthenia, 21 (59.5%) had cough, 29 (73.8%) had perversion or loss of sense of smell, pain, and throat discomfort. The duration of symptoms varied from 34 days to 34 weeks. Within a month after the end of the acute disease period, 8 (20%) patients had a decrease in working capacity, 13 (33%) had difficulty breathing, 9 (22%) had a cough, and 4 (10%) had pain and sore throat. During severe acute respiratory syndrome 2 infection, the virus activates the innate and adaptive immunity, resulting in the formation of specific class G immunoglobulins to the pathogens. After leveling the clinical manifestations, class G immunoglobulins were detected in the majority of convalescents (79%90%) during the first 6 months, starting from day 14 from disease onset with a predominantly high ( 10 conl. units) positivity coefficient. Moreover, this pattern occurred in both men and women; however, in some studies, the levels of the positivity coefficient of class G immunoglobulins began to decrease by the fifth month of follow-up and sometimes at an earlier time (2 months). Perhaps, this is due to the different functional activities of the immune system of each convalescent, infecting dose of the pathogen, and peculiarities of its interaction with the macroorganism and its immune system. Nevertheless, the class G immunoglobulins identified in the study do not yet indicate the probability of reinfection of convalescents with the same pathogen. The protective titer of antibodies has yet to be investigated further.Keywords
This publication has 23 references indexed in Scilit:
- COVID-19 pandemic in Saint Petersburg, Russia: combining surveillance and population-based serological study data in May, 2020–April, 2021medRxiv, 2021
- Long‐term monitoring of the development and extinction of IgA and IgG responses to SARS‐CoV‐2 infectionJournal of Medical Virology, 2021
- Immune dysregulation and system pathology in COVID-19Virulence, 2021
- The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 InfectionsJournal of Neuroimmune Pharmacology, 2020
- SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responsesNature Communications, 2020
- Profile of specific antibodies to SARS-CoV-2: The first reportJournal of Infection, 2020
- Efficacy of methylprednisolone pulse therapy in patients with COVID-19Clinical Microbiology and Antimicrobial Chemotherapy, 2020
- Convalescent plasma as a potential therapy for COVID-19The Lancet Infectious Diseases, 2020
- The Novel Coronavirus Originating in Wuhan, ChinaJAMA, 2020
- Change in anti-SARS-CoV-2 IgG antibodies (COVID-19) among the population of the Russian Federation regions and in convalescents in dynamicsConsilium Medicum, 2020